ATF6 activation alters colonic lipid metabolism causing tumor-associated microbial adaptation

Olivia I. Coleman, Adam Sorbie, Sandra Bierwith, Janine Kövilein, Miriam von Stern, Nikolai Köhler, Jakob Wirbel, Christina Schmidt, Tim Kacprowski, Andreas Dunkel, Josh K. Pauling, Johannes Plagge, Diego Mediel-Cuadra, Sophia Wagner, Tingying Peng, Thomas J. Metzler, Clemens Schafmayer, Sebastian Hinz, Christian Röder, Christoph Röcken, Bärbel Stecher, Philip Rosenstiel, Katja Steiger, Moritz Jesinghaus, Gerhard Liebisch, Josef Ecker, Georg Zeller, Klaus‐Peter Janssen, Dirk Haller, Klaus-Peter JanssenbioRxiv 2023 · DOI

TL;DR

This study reveals a crucial link between the endoplasmic reticulum stress response protein ATF6 and colorectal cancer (CRC) development. It shows that ATF6 activation in the gut lining alters lipid metabolism, which in turn promotes the growth of specific bacteria that drive tumor formation. This discovery highlights a novel therapeutic avenue by targeting this ATF6-lipid-microbiota axis.

What Problem Does This Paper Address?

Colorectal cancer (CRC) is a major health challenge, and understanding its complex development is key to finding better treatments. While the unfolded protein response (UPR) in the endoplasmic reticulum (ER) is known to play a role in cancer, the specific contribution of its component, ATF6, and how it interacts with the gut microbiome in CRC, remained unclear. This paper addresses this gap by investigating the clinical relevance of ATF6 in CRC patients and elucidating its mechanistic role in promoting tumorigenesis through alterations in lipid metabolism and subsequent impact on the gut microbiota.

Methods

The researchers employed a multi-pronged approach:

  • Human Cohort Analysis: They quantified ATF6 protein expression in multiple independent German CRC patient cohorts using immunohistochemistry (IHC) and AI-based image analysis (QuPath).
  • Murine Models: They utilized transgenic ATF6-expressing mice (nATF6IEC) under both specific pathogen-free (SPF) and germ-free (GF) conditions to study tumor development and transcriptional responses.
  • Transcriptomics: Bulk mRNA sequencing was performed on colonic epithelial cells from these mice to identify differentially expressed genes and pathways.
  • Metabolomics: Untargeted metabolomics (LC-TOF-MS and LC-MS/MS) was used to analyze cecal content and CRC patient tissue, focusing on lipid profiles.
  • Ex Vivo Experiments:
    • Organoid Cultures: Intestinal organoids were used to study ATF6-mediated fatty acid elongation independently of microbial and immune signals.
  • BONCAT and FACS: Bioorthogonal non-canonical amino acid tagging (BONCAT) combined with fluorescence-activated cell sorting (FACS) was employed to identify bacteria actively growing in response to long-chain fatty acids (LCFAs).
  • Microbiota Transfer: Fecal microbiota transplantation (FMT) from FASN inhibitor-treated mice to germ-free mice was used to assess the causal role of the microbiota in ATF6-driven tumorigenesis.
  • Bioinformatics: Various computational tools were used for data analysis, including KEGG pathway analysis, signature regulatory clustering (SiRCIe), sPLS-DA for multi-omics integration, and PICRUSt2 for predicting functional potential of the microbiome.

Datasets

  • Human CRC Patient Cohorts:
    • Cohort 1: 959 CRC patients (IHC analysis).
  • Cohort 2: 50 CRC patients (AI model training and testing).
  • Cohort 3: 55 EOCRC and 256 LOCRC patients (IHC analysis).
  • Cohort 4: 259 EOCRC and LOCRC patients (LC-MS analysis).
  • Public Databases: Pan-Cancer Atlas (n=10,967 cases) and TCGA (n=640 CRC cases) were screened for genomic amplifications/gains.
  • Murine Datasets: RNA sequencing data from nATF6IEC mice (SPF and GF) at different time points.
  • Publicly Available Data: 16S rRNA gene amplicon sequencing data from The Cancer Genome Atlas (TCGA) dataset was used for computational inference of transcription factor activity.

Key Insights and Ideas

  • ATF6 as a CRC Biomarker: A significant subpopulation of CRC patients (19-38% in LOCRC, 11% in EOCRC) exhibits high ATF6 expression, suggesting its clinical relevance.
  • Lipid Metabolism Rewiring: ATF6 activation directly drives alterations in fatty acid metabolism, specifically promoting fatty acid elongation, even in the absence of microbial or immune signals.
  • Microbiota as a Driver of Tumorigenesis: The study strongly suggests that ATF6-induced changes in lipid metabolism create an environment that favors the growth of specific, tumor-promoting bacteria. This isn't just a correlation; the microbiota from ATF6-altered environments causally influences tumor development.
  • Selective Bacterial Activation: Long-chain fatty acids (LCFAs), which are upregulated due to ATF6, selectively activate the growth and translational activity of certain bacteria, including known tumor-associated taxa like Desulfovibrio fairfieldensis.
  • Triangular Interplay: The research highlights a critical interplay between cellular stress responses (ATF6), host metabolism (lipid metabolism), and the gut microbiome in CRC pathogenesis.

Key Results

  • ATF6 Expression in CRC: 19-38% of late-onset CRC patients and 11% of early-onset CRC patients showed high ATF6 expression.
  • Fatty Acid Metabolism: ATF6 activation led to the upregulation of 23 fatty acid metabolism-related genes and significantly increased long-chain fatty acids (LCFAs) in colonic tissue.
  • FASN Inhibition: Inhibiting fatty acid synthase (FASN) in ATF6-transgenic mice completely prevented colon tumor formation.
  • Microbiota Transfer: Transferring microbiota from FASN inhibitor-treated mice to germ-free mice significantly reduced tumor incidence and volume in recipient mice.
  • Bacterial Activation: LCFAs selectively activated the growth of specific bacteria, including Desulfovibrio fairfieldensis, which was also enriched in ATF6-high mice.
  • Human-Microbe Link: ATF6 activity in CRC patients positively correlated with the presence of CRC-enriched bacterial genera, including Desulfovibrio.

Limitations and Future Work

  • Mechanistic Detail: While the study establishes a strong link, further work is suggested to fully elucidate the precise mechanisms by which ATF6 signaling influences lipid metabolism and how this, in turn, shapes the microbiota.
  • Single-Cell Transcriptomics: The authors propose future research using single-cell transcriptomics to characterize the ATF6 transcriptional response at a finer cellular level.
  • Gnotobiotic Mouse Experiments: Extending gnotobiotic mouse experiments with individual bacterial candidates is recommended to identify causal tumor drivers and elucidate mechanisms of tumor initiation.
  • Therapeutic Potential: The identified ATF6-lipid-microbiota axis presents "targetable vulnerabilities in CRC" that warrant further investigation for potential prevention and treatment strategies.

Summary updated

Abstract

Abstract Endoplasmic reticulum unfolded protein responses (UPR ER ) contribute to cancer development and the activating transcription factor 6 (ATF6) is involved in microbiota-dependent tumorigenesis. Here, we substantiate the clinical relevance of ATF6 in early-onset and late colorectal cancer patient cohorts. Transcriptional analysis in intestinal epithelial cells (IEC) of ATF6 transgenic mice (nATF6 IEC ) identified bacteria-specific changes in cellular metabolism enriched for fatty acid biosynthesis. Untargeted metabolomics and isotype-labeling confirmed ATF6-related enrichment of long chain fatty acids in colonic tissue of patients, mice and organoid cultures. FASN inhibition and microbiota transfer in germ-free nATF6 IEC mice confirmed the causal involvement of ATF6-induced lipid alterations in tumorigenesis. The selective expansion of tumor-relevant microbial taxa was mechanistically linked to long chain fatty acid exposure, using bioorthogonal non-canonical amino acid tagging (BONCAT) and growth analysis of Desulfovibrio isolates. We postulate chronic ATF6 signaling in the epithelium to select for tumor-promoting microbiota by altering lipid metabolism. Abstract Figure Graphical Abstract: Chronic ATF6 signaling in the colonic epithelium alters lipid metabolism to select a tumor-promoting microbiota Biallelic expression of activated ATF6 (p50 nuclear fragment) in intestinal epithelial cells (nATF6 IEC ) induces spontaneous colon tumors in SPF but not GF mice Mechanistically, biallelic SPF nATF6 IEC mice alter colonic lipid metabolism, including the upregulation of LCFAs and Fasn Inhibition of FASN prevents colon tumor formation in mice, and reduces the tumor-promoting potential of the intestinal microbiota (FMT) Exposure of fl/fl control mouse microbiota to LCFAs ex vivo translationally activates tumor-associated bacteria, including Desulfovibrio fairfieldensis Human CRC patients show ATF6 upregulation, FASN co-occurrence and increased LCFAs in T tissue ATF6 activity links with CRC-associated microbiota in patients, including Desulfovibrio Created with BioRender.com nATF6: activated activating transcription factor 6; LCFA: long-chain fatty acids; SAFA: saturated fatty acids; Fasn: fatty acid synthase; C75 i.p.: intraperitoneal injection of the Fasn inhibitor C75.
BibTeX
@misc{coleman2023atf,
  author = {Olivia I. Coleman and Adam Sorbie and Sandra Bierwith and Janine Kövilein and Miriam von Stern and Nikolai Köhler and Jakob Wirbel and Christina Schmidt and Tim Kacprowski and Andreas Dunkel and Josh K. Pauling and Johannes Plagge and Diego Mediel-Cuadra and Sophia Wagner and Tingying Peng and Thomas J. Metzler and Clemens Schafmayer and Sebastian Hinz and Christian Röder and Christoph Röcken and Bärbel Stecher and Philip Rosenstiel and Katja Steiger and Moritz Jesinghaus and Gerhard Liebisch and Josef Ecker and Georg Zeller and Klaus‐Peter Janssen and Dirk Haller and Georg Zeller and Klaus-Peter Janssen and Dirk Haller},
  title = {{ATF6 activation alters colonic lipid metabolism causing tumor-associated microbial adaptation}},
  year = {2023},
  doi = {10.1101/2023.11.03.565267},
  howpublished = {bioRxiv},
}
Figure